OncoMatch/Clinical Trials/NCT07362459
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Is NCT07362459 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including SCTB14 and Pembrolizumab for non-small cell lung carcinoma (nsclc).
Treatment: SCTB14 · Pembrolizumab — This Phase III, randomized, double-blind study compares the efficacy and safety of SCTB14 versus pembrolizumab as first-line treatment in patients with driver gene-negative, TPS ≥10% locally advanced or metastatic non-small cell lung cancer (NSCLC). The primary objective is to assess superiority of SCTB14 over pembrolizumab in prolonging progression-free survival. Safety will be closely monitored.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation (wild-type)
confirmation of the absence of EGFR sensitizing mutations ... is required prior to enrollment
Required: ALK rearrangement (wild-type)
confirmation of the absence of ... ALK gene rearrangements ... is required prior to enrollment
Required: PD-L1 (CD274) overexpression (TPS ≥ 10%)
Subjects must provide a histology sample suitable for PD-L1 testing, with a Tumor Proportion Score (TPS) ≥ 10%
Required: ROS1 fusion (wild-type)
Known actionable driver gene mutations such as ROS1 fusion ... [excluded]
Required: BRAF V600E (wild-type)
Known actionable driver gene mutations such as ... BRAF V600E mutation ... [excluded]
Required: NTRK1 fusion (wild-type)
Known actionable driver gene mutations such as ... NTRK fusion ... [excluded]
Required: NTRK2 fusion (wild-type)
Known actionable driver gene mutations such as ... NTRK fusion ... [excluded]
Required: NTRK3 fusion (wild-type)
Known actionable driver gene mutations such as ... NTRK fusion ... [excluded]
Required: MET exon 14 skipping mutation (wild-type)
Known actionable driver gene mutations such as ... MET exon 14 skipping mutation ... [excluded]
Required: RET fusion (wild-type)
Known actionable driver gene mutations such as ... RET fusion mutation ... [excluded]
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-tumor therapy
No prior systemic anti-tumor therapy for the studied disease
Cannot have received: antitumor immunotherapy
Prior treatment with antitumor immunotherapy
Cannot have received: antiangiogenic therapy
Prior treatment with ... antiangiogenic therapy
Cannot have received: small molecule tyrosine kinase inhibitor
Prior treatment with ... small molecule tyrosine kinase inhibitor (TKI)-based antitumor drugs
Cannot have received: thoracic radiotherapy
Prior thoracic radiotherapy
Cannot have received: local anti-tumor therapy
Exception: within 2 weeks before first dosing
local anti-tumor therapy within 2 weeks before first dosing
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify